PD Dr. rer. nat. Andras Bilkei Gorzo

Better life quality and improved health care led to a significant increase in human lifespan and thus in the ration of elderly in the population of most developed countries.

The healthy, disease-free lifespan, the so-called health-span did not increase as much as lifespan, because the incidence of debilitating chronic diseases like dementias strongly increases in advanced age. As a consequence, now approximately 16-20 % of a human life is spent in late-life morbidity. Slowing down the ageing process would lead to a delay of the onset or decrease of the severity of late-life morbidities, which is one of the major aims in societies of the developed countries. He was the first who suggested that cannabinoid system may protect against ageing, because deletion of CB1 receptors led to early onset and accelerated brain ageing.

Following this new research direction he showed that 1; cannabinoid system activity declines with ageing. 2; Reduced cannabinoid system activity is associated with pro-inflammatory glial activity, reduced neurogenesis, disturbed proteostasis, cognitive deficits. -typical signs of old age. 3; elevation of CB1 receptor activity in old individuals by chronic low dose THC treatment reversed age-related gene expression, epigenetic and functional changes to the level typical of young individuals.

In his present projects he plans to elucidate whether a long-lasting restoration of cannabinoid signalling through THC-treatment – with or without senolytic treatment increases life- and health-span.

ResearchGate

University of Bonn

Institute of Molecular Psychiatry

Venusberg-Campus 1, Blgd. 76

53127 Bonn

Germany

CV

Education

2009 Habilitation at the University of Bonn, Germany

2001 PhD graduation in biology at the “Eotvos Lorand” University of Sciences, Budapest, Hungary

1994 PhD graduation in biochemistry at the “Eotvos Lorand” University of Sciences, Budapest, Hungary

1986 Diploma in biology and biotechnology at the “Eotvos Lorand” University of Sciences, Budapest, Hungary

Position Held

Since 2004 Head of the Group of Behavioral Pharmacology

Institute of Molecular Psychiatry, University of Bonn, Germany

2001 - 2004 Research fellow

Department of Molecular Neurobiology, University of Bonn, Germany

1993 - 2000 Research fellow

EGIS Pharmaceuticals Ltd., Budapest, Hungary

1991 - 1993 Research fellow

Chinoin Pharmaceutical Works Ltd., Budapest, Hungary

1990 - 1991 Head of the Biological Research Department

Alkaloida Chemical Factory, Tiszavasvari, Hungary

1986 - 1990 Research fellow

Alkaloida Chemical Factory, Tiszavasvari, Hungary

Membership in Scientific Organizations

Hungarian Gerontological Society

Hungarian Neurological Society

European Neurological Association

Pro´jects/Fundings

Projekttitel D

Duration:

bis 2027

Head:

PD Dr. rer. nat. Andras Bilkei Gorzo

Funders:

DFG

Latest Publications

Bidirectional Effect of Long-Term Δ9‑Tetrahydrocannabinol Treatment on mTOR Activity and Metabolome

Andras Bilkei-Gorzo,* Britta Schurmann, Marion Schneider, Michael Kraemer, Prakash Nidadavolu,
Eva C. Beins, Christa E. Müller, Mona Dvir-Ginzberg, and Andreas Zimmer

Source: ACS Pharmacology & Translational Science,

Link: https://doi.org/10.1021/acsptsci.4c00002

Published August 2024

more...

Local cannabinoid receptor type-1 regulates glial cell activity and insulin-like growth factor-1 receptor signaling in the mediobasal hypothalamus

Michela Palmisano 1 , Carla Florencia Ramunno 2 , Eli Farhat 3 , Mona Dvir-Ginzberg 3 , Beat Lutz 4 , Carmen Ruiz de Almodovar 2 , Andras Bilkei-Gorzo 5

Source: Elsevier, Mech Ageing Dev (PMID: 38821184 DOI: 10.1016/j.mad.2024.111954)
Published May 2024

Link

Possible role of locus coeruleus neuronal loss in age-related memory and attention deficits

Gargano, A (Gargano, Alessandra) [1] ; Olabiyi, BF (Olabiyi, Bolanle Fatimat) [1] ; Palmisano, M (Palmisano, Michela) [1] ; Zimmer, A (Zimmer, Andreas) [1] ; Bilkei-Gorzo, A (Bilkei-Gorzo, Andras)

Source: FRONTIERS IN NEUROSCIENCE
Published August 2023

Link